JP2018523105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523105A5 JP2018523105A5 JP2017563088A JP2017563088A JP2018523105A5 JP 2018523105 A5 JP2018523105 A5 JP 2018523105A5 JP 2017563088 A JP2017563088 A JP 2017563088A JP 2017563088 A JP2017563088 A JP 2017563088A JP 2018523105 A5 JP2018523105 A5 JP 2018523105A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- subject
- crbn
- ratio
- therapeutic compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 68
- 239000000090 biomarker Substances 0.000 claims description 53
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 39
- 230000001225 therapeutic effect Effects 0.000 claims description 36
- 239000000523 sample Substances 0.000 claims description 26
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 claims description 23
- 102100037796 Zinc finger protein Helios Human genes 0.000 claims description 23
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 claims description 18
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 208000032839 leukemia Diseases 0.000 claims description 10
- 239000013068 control sample Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims description 5
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims description 5
- 201000006966 adult T-cell leukemia Diseases 0.000 claims description 5
- 238000003753 real-time PCR Methods 0.000 claims description 4
- 239000013074 reference sample Substances 0.000 claims description 4
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 3
- 229960004942 lenalidomide Drugs 0.000 claims description 3
- 230000004043 responsiveness Effects 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 102100032783 Protein cereblon Human genes 0.000 claims 23
- 102000015367 CRBN Human genes 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 17
- 239000000203 mixture Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170099P | 2015-06-02 | 2015-06-02 | |
| US62/170,099 | 2015-06-02 | ||
| US201562237905P | 2015-10-06 | 2015-10-06 | |
| US62/237,905 | 2015-10-06 | ||
| PCT/US2016/035198 WO2016196580A1 (en) | 2015-06-02 | 2016-06-01 | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018523105A JP2018523105A (ja) | 2018-08-16 |
| JP2018523105A5 true JP2018523105A5 (cg-RX-API-DMAC7.html) | 2019-05-16 |
| JP6585737B2 JP6585737B2 (ja) | 2019-10-02 |
Family
ID=57441615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563088A Active JP6585737B2 (ja) | 2015-06-02 | 2016-06-01 | セレブロン関連タンパク質の比を使用してがんの治療のための薬物の有効性を決定するための方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10338077B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3304076A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6585737B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016196580A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| AU2016326499A1 (en) | 2015-09-25 | 2018-04-12 | Celgene Corporation | Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| ES3042541T3 (en) | 2016-01-08 | 2025-11-21 | Celgene Corp | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| EP3422002B1 (de) | 2017-06-26 | 2020-04-08 | Bioscientia Institut für Medizinische Diagnostik GmbH | Screeningverfahren zur diagnose einer hämatologischen neoplasie |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CR20210001A (es) | 2018-07-10 | 2021-04-19 | Novartis Ag | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteina con dedos de zinc 2 de la familia ikaros (1kzf2) |
| CA3114942A1 (en) * | 2018-10-04 | 2020-04-09 | Alfred Health | Methods for monitoring response to treatment |
| CA3119526A1 (en) * | 2018-12-03 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of helios and methods of use |
| WO2020128972A1 (en) * | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| AU2021413227A1 (en) | 2020-12-31 | 2023-07-13 | Elephas Biosciences Corporation | Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012125405A2 (en) * | 2011-03-11 | 2012-09-20 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing responsiveness to lenalidomide, thalidomide, and/or other thalidomide analogs |
| WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| EP3904875B1 (en) * | 2012-06-29 | 2024-11-20 | Celgene Corporation | Methods for determining drug efficacy using ikzf3 (aiolos) |
| WO2014039960A1 (en) * | 2012-09-10 | 2014-03-13 | Celgene Corporation | Methods for the treatment of locally advanced breast cancer |
| JP2016521280A (ja) * | 2013-05-03 | 2016-07-21 | セルジーン コーポレイション | 併用療法を用いて癌を治療する方法 |
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| KR20160090390A (ko) | 2013-12-06 | 2016-07-29 | 셀진 코포레이션 | 혈액암의 치료방법 및 바이오마커를 사용한 레날리도마이드에 대한 임상적 민감도의 예측방법 |
| JP2017533727A (ja) | 2014-10-13 | 2017-11-16 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 |
| JP2018523823A (ja) | 2015-08-04 | 2018-08-23 | セルジーン コーポレイション | 慢性リンパ球性白血病の治療方法及び免疫調節療法に対する臨床的感度の予測因子としてのバイオマーカーの利用 |
| EP3334844A4 (en) | 2015-08-12 | 2019-11-06 | Celgene Corporation | METHOD FOR THE TREATMENT OF SOLID TUMORS AND USE OF BIOMARKERS AS PREDICTORS OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES |
| AU2016326499A1 (en) | 2015-09-25 | 2018-04-12 | Celgene Corporation | Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| ES3042541T3 (en) | 2016-01-08 | 2025-11-21 | Celgene Corp | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
-
2016
- 2016-06-01 US US15/170,789 patent/US10338077B2/en active Active
- 2016-06-01 WO PCT/US2016/035198 patent/WO2016196580A1/en not_active Ceased
- 2016-06-01 EP EP16804297.6A patent/EP3304076A4/en active Pending
- 2016-06-01 JP JP2017563088A patent/JP6585737B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018523105A5 (cg-RX-API-DMAC7.html) | ||
| Vermeire et al. | Laboratory markers in IBD: useful, magic, or unnecessary toys? | |
| Willumsen et al. | Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls | |
| JP2017524130A5 (cg-RX-API-DMAC7.html) | ||
| EP3458610B1 (en) | Therapeutic treatment of breast cancer based on c-maf status | |
| JP2013179945A (ja) | 分類予測を使用した肺障害についての診断 | |
| JP2016507066A5 (cg-RX-API-DMAC7.html) | ||
| Ward et al. | Evaluation of serum and tissue levels of VAP-1 in colorectal cancer | |
| Arakawa et al. | Clinical significance of tissue factor pathway inhibitor 2, a serum biomarker candidate for ovarian clear cell carcinoma | |
| Luo et al. | Serpin peptidase inhibitor, clade A member 3 (SERPINA3), is overexpressed in glioma and associated with poor prognosis in glioma patients | |
| CN106662543A (zh) | 肺癌患者中的非侵入性基因突变检测 | |
| US10585102B2 (en) | Characterization of cancer using detection of activated leukocyte cell adhesion molecule (ALCAM) shedding | |
| Yan et al. | Significance of tumour cell HLA‐G5/‐G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients | |
| Edfeldt et al. | DcR3, TFF3, and midkine are novel serum biomarkers in small intestinal neuroendocrine tumors | |
| Štemberger et al. | Osteopontin is associated with decreased apoptosis and αv integrin expression in lung adenocarcinoma | |
| WO2014198995A1 (es) | Biomarcadores para el diagnóstico y respuesta al tratamiento en cáncer de páncreas | |
| Miyata et al. | Alteration of prognostic efficacy of albumin‐bilirubin grade and Child‐Pugh score according to liver fibrosis in hepatocellular carcinoma patients with Child‐Pugh A following hepatectomy | |
| WO2014172447A1 (en) | Compositions and methods for diagnosing lung cancers | |
| Roshdy et al. | Long non-coding RNA HOTAIR and HOTTIP as potential biomarkers for hepatitis C virus genotype 4-induced hepatocellular carcinoma | |
| Srivastava et al. | Prognostic role of Androgen Receptor splice variant 7 (AR-V7) in the pathogenesis of breast cancer | |
| Liao et al. | Astrocyte elevated gene-1 (AEG-1) is a marker for aggressive salivary gland carcinoma | |
| Michlmayr et al. | Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value | |
| González‐Santiago et al. | TGF‐β1 serum concentration as a complementary diagnostic biomarker of lung cancer: establishment of a cut‐point value | |
| Marioni et al. | Neoangiogenesis in laryngeal carcinoma: angiogenin and CD105 expression is related to carcinoma recurrence rate and disease‐free survival | |
| Wang et al. | Clinicopathological significance of SLP-2 overexpression in human gallbladder cancer |